[Myoanabolic steroids and selective androgen receptor modulators: mechanism of action and perspectives]
- PMID: 19861292
- DOI: 10.1556/OH.2009.28739
[Myoanabolic steroids and selective androgen receptor modulators: mechanism of action and perspectives]
Abstract
Interest in anabolic steroids has been renewed in the last decade with the discovery of tissue-selective androgen receptor modulators exhibiting high myotropic and small androgenic activity. An explanation put forward by us in 1982 for the mechanism of the preferential myotropic effect of nandrolone (19-nortestosterone) exploits the fundamental difference between the 5alpha-reductase concentrations in skeletal muscle and androgenic target tissue. In androgenic tissue, testosterone is converted to the more potent 5alpha-dihydrotestosterone whereas nandrolone is converted to a less potent derivative. As 5alpha-reduction is negligible in skeletal muscle, this explains why nandrolone shows a greater myotropic to androgenic ratio when compared with testosterone. Anabolic steroids that do not undergo 5alpha-reduction exert myotropic-androgenic dissociation because their effect in androgenic tissues is not amplified by 5alpha-reduction. Tissue selectivity by receptor modulators may be achieved by inducing specific conformational changes of the androgen receptor that affect its interaction with transcriptional coregulators. Anabolic activity is mediated by the stimulation of ribosomal RNA synthesis therefore regulation of this synthesis by anabolic steroids would deserve detailed studies.
Similar articles
-
Mechanism of action of bolandiol (19-nortestosterone-3beta,17beta-diol), a unique anabolic steroid with androgenic, estrogenic, and progestational activities.J Steroid Biochem Mol Biol. 2010 Feb 15;118(3):151-61. doi: 10.1016/j.jsbmb.2009.11.008. Epub 2009 Nov 24. J Steroid Biochem Mol Biol. 2010. PMID: 19941958 Free PMC article.
-
Tissue selectivity and potential clinical applications of trenbolone (17beta-hydroxyestra-4,9,11-trien-3-one): A potent anabolic steroid with reduced androgenic and estrogenic activity.Steroids. 2010 Jun;75(6):377-89. doi: 10.1016/j.steroids.2010.01.019. Epub 2010 Feb 4. Steroids. 2010. PMID: 20138077 Review.
-
Selective androgen receptor modulators: in pursuit of tissue-selective androgens.Curr Opin Investig Drugs. 2006 Oct;7(10):873-81. Curr Opin Investig Drugs. 2006. PMID: 17086931 Review.
-
The potent synthetic androgens, dimethandrolone (7α,11β-dimethyl-19-nortestosterone) and 11β-methyl-19-nortestosterone, do not require 5α-reduction to exert their maximal androgenic effects.J Steroid Biochem Mol Biol. 2010 Oct;122(4):212-8. doi: 10.1016/j.jsbmb.2010.06.009. Epub 2010 Jun 25. J Steroid Biochem Mol Biol. 2010. PMID: 20599615 Free PMC article.
-
5alpha-reduction of norethisterone enhances its binding affinity for androgen receptors but diminishes its androgenic potency.J Steroid Biochem Mol Biol. 1997 Jan;60(1-2):121-9. doi: 10.1016/s0960-0760(96)00172-0. J Steroid Biochem Mol Biol. 1997. PMID: 9182866
Cited by
-
Molecular mechanisms and therapeutic interventions in sarcopenia.Osteoporos Sarcopenia. 2017 Sep;3(3):117-122. doi: 10.1016/j.afos.2017.08.098. Epub 2017 Sep 27. Osteoporos Sarcopenia. 2017. PMID: 30775515 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials